Search the Newsreel

MaxCyte revenue down 15% to USD 7.3M in Q2 2026

MaxCyte, Inc. reported its Q2 2026 financial results, showing a 15% decrease in total revenue to $7.3 million compared to Q2 2025. Despite the revenue dip, the company exceeded expectations due to strong instrument placements and stable processing assembly sales, and significantly reduced its …

MaxCyte, Inc. $MXCT Shares Acquired by Renaissance Technologies LLC

Renaissance Technologies LLC significantly increased its stake in MaxCyte, Inc. (NASDAQ:MXCT) by 153.3% in the first quarter, acquiring an additional 1.206 million shares to own a total of 1.993 million shares, representing 1.86% of the company. Other institutional investors also built positions, with hedge …

Price to sales forward of MaxCyte, Inc. – MUN:MYE0

This page from TradingView provides financial information for MaxCyte, Inc. (MUN:MYE0), specifically focusing on its forward price-to-sales ratio. The article indicates that market data is provided by ICE Data Services and reference data by FactSet, with SEC filings from Quartr.

MaxCyte Q2 Results: EPS beats estimates, revenue falls 14.5% YoY

MaxCyte Inc. reported Q2 2026 results, with EPS beating estimates at $(0.08) despite a 14.53% year-over-year revenue decrease to $7.271 million. The company narrowed its net loss by 33.33% and announced a new strategic partnership with Genentech. MaxCyte also reaffirmed its full-year 2026 revenue …

MaxCyte Inc (MXCT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Enterprise ...

MaxCyte Inc. reported a 15% decrease in total revenue for Q2 2026, reaching $7.3 million, with core revenue down 21%. Despite this, the company exceeded expectations and highlighted significant growth in CASGEVY royalties and a new enterprise-level partnership with Genentech to diversify revenue streams. …

MaxCyte narrows Q2 2026 loss 28%, signs Genentech deal

MaxCyte (NASDAQ:MXCT) Issues Earnings Results

MaxCyte (NASDAQ:MXCT) reported a slight beat on earnings with an adjusted loss of $0.08 per share against an expected $0.09 loss, and revenue of $6.5 million, largely meeting estimates. The company reaffirmed its 2026 revenue guidance of $30 million–$32 million, anticipating instrument placements to …

Earnings call transcript: MaxCyte tops Q2 2026 revenue forecast, shares fall

MaxCyte reported Q2 2026 revenue of $7.3 million, exceeding analyst expectations, though shares fell after hours due to a year-over-year sales decline and lower margins. The company highlighted stabilization in the cell therapy market and a new enterprise partnership with Genentech as key developments. …

$MXCT ($MXCT) Releases Q2 2026 Earnings

MaxCyte Reports Second Quarter 2026 Financial Results

MaxCyte, Inc. announced its financial results for the second quarter ended June 30, 2026, reporting total revenue of $7.3 million, a 15% decrease year-over-year, and a net loss of $8.9 million, an improvement from the $12.4 million loss in Q2 2025. The company reiterated …

MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates

MaxCyte, Inc. (MXCT) reported a Q2 loss of $0.08 per share, exceeding the Zacks Consensus Estimate of a $0.12 loss, and surpassed revenue estimates with $7.27 million. Despite beating earnings and revenue expectations in some recent quarters, the stock has underperformed the market this …

Tranche Update on MaxCyte, Inc.'s Equity Buyback Plan announced on May 12, 2026.

MaxCyte, Inc. has provided an update on its equity buyback plan announced on May 12, 2026. As of August 12, 2026, the company has repurchased 4,730,105 shares, representing 4.42% of its stock, for a total of $5.5 million. This repurchase completes the program initiated …

MaxCyte (MXCT) Q1 2026 Earnings: Narrower Loss Beats Estimates as Shares Rise 6.31% - Revenue Estimate Trend

MaxCyte | 4: Statement of changes in beneficial ownership of securities-Director Johnston John Joseph

This document is a statement of changes in beneficial ownership of securities for Director Johnston John Joseph at MaxCyte. These types of filings are routine disclosures required for company insiders. The specific details of the changes in ownership are contained within the document.

Latest MXCT ETF News Today | Earnings, Events & Price Alerts

This page provides the latest news and updates for MXCT ETF, including earnings reports, significant partnerships, and strategic developments. Recent headlines cover MaxCyte's collaborations with Genentech and Adicet Bio, Q4 2025 earnings results and forecasts for 2026 revenue, and executive appointments. The company has …

MaxCyte (MXCT) Expected to Post Earnings on Wednesday

River Global Investors Discloses Investment at MaxCyte with 0.78% Stake

River Global Investors LLP has disclosed a 0.78% stake in MaxCyte, Inc. common stock as of July 31, 2026. This change in holdings follows a corporate restructuring at River Global Investors' parent company, with Liontrust Investment Partners LLP assuming responsibility for certain funds and …

MaxCyte, Inc. (MXCT) holder River Global shifts 4.3% voting stake

River Global Investors LLP has reported a significant shift in its holding of MaxCyte, Inc. (MXCT) shares. Following the FCA's approval of a change in control and acquisition of River Global Holdings Limited, approximately 4.3% of MaxCyte voting rights transferred from River Global Investors …

MaxCyte Inc (MXCT) Earnings Forecast: Future EPS & Revenue Growth Estimates

BlackRock (MXCT holder) discloses 1,402,591 MaxCyte shares, a 1.3% ownership stake

BlackRock, Inc. has disclosed a 1.3% ownership stake in MaxCyte, Inc. common stock, amounting to 1,402,591 shares as of June 30, 2026. This information comes from an amended Schedule 13G/A SEC filing, indicating BlackRock holds sole voting and dispositive power over these shares. The …

MaxCyte Inc (MXCT) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for MaxCyte Inc (MXCT), highlighting its current risk score and beta value. The company's risk score is 2.63, ranking it 147 out of 199 in the Healthcare Equipment & Supplies industry. With a beta of 1.45, MXCT stock …

MXCT|MaxCyte Inc|Price:1.050|Chg%:+0.030

The article provides a comprehensive stock analysis of MaxCyte Inc (MXCT), highlighting its healthy fundamentals, high growth potential, and fair valuation within the Healthcare Equipment & Supplies industry. It notes strong institutional ownership and a "Buy" rating from multiple analysts with a significant upside …

MaxCyte Inc (MXCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of MaxCyte Inc (MXCT), detailing its current price momentum, support and resistance levels, and indicator readings. The stock is currently trading between $0.87 and $1.33, with a neutral overall signal based on moving averages and other technical indicators. …

MaxCyte Inc (MXCT) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of MaxCyte Inc (MXCT), highlighting its current valuation score of 7.64 and its ranking within the Healthcare Equipment & Supplies industry. It notes the company's current P/E ratio is -2.78, which is significantly lower than its recent high …

MaxCyte Inc (MXCT) Institutional Confidence

MaxCyte Inc (MXCT) currently holds an institutional shareholding score of 7.00, placing it 78th out of 199 companies in the Healthcare Equipment & Supplies industry. Institutional investors hold 74.61% of shares, a slight decrease of 0.07% over the last quarter. James Simons is the …

MaxCyte Inc (MXCT) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of MaxCyte Inc's (MXCT) dividend history and stock split events. It states that MaxCyte Inc has not distributed any dividends over the past five years. The page also displays current stock information such as price, market cap, and links …

MaxCyte, Inc. Revenue Breakdown – DUS:MYE0

MaxCyte, Inc. generated €28.12 million in revenue last year, with its top-performing segment, PA Revenue, contributing €10.12 million. The majority of the company's revenue came from the United States, which accounted for €17.95 million.

MaxCyte Inc (MXCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for MaxCyte Inc (MXCT) for the fiscal year 2024, updated on April 6. It categorizes revenue by business segments, showing that product sales account for 56.59% and licenses for 37.45%. Geographically, 63.82% of the revenue originates from …

Stifel Maintains MaxCyte(MXCT.US) With Buy Rating, Maintains Target Price $4

Stifel has reiterated its Buy rating for MaxCyte (MXCT.US) and maintained its target price of $4. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance and valuation.

MaxCyte stock surges on Genentech technology license deal By Investing.com

MaxCyte Inc. shares surged 5.6% following a technology license partnership announcement with Genentech, a Roche Group member. The deal grants Genentech access to MaxCyte’s ExPERT GTx platform to advance cell therapy programs from research to manufacturing. This collaboration aims to enhance cell engineering and …

Brooklands Fund Management Ltd Invests $1.54 Million in MaxCyte, Inc. $MXCT

Brooklands Fund Management Ltd has invested approximately $1.54 million in MaxCyte, Inc. by acquiring 2.19 million shares, making it their 17th largest holding. MaxCyte, a cell therapy platform company, has also seen increased interest from other institutional investors, with 68.81% of its stock now …

Genentech Gets Access to MaxCyte Cell-Engineering Platforms

MaxCyte (Nasdaq: MXCT) announced a technology license partnership with Genentech, a member of the Roche Group, to advance cell therapy programs. This agreement grants Genentech access to MaxCyte's ExPERT GTx platform and other technologies to support ex vivo cell engineering applications across research, clinical …

MaxCyte Grants Roche Cell Therapy Tech License

MaxCyte has granted Genentech, a member of the Roche Group, a multi-platform technology license for its cell-engineering technologies. This agreement provides Genentech with non-exclusive access to MaxCyte's ExPERT GTx platform and other technologies for use across multiple research, clinical development, and manufacturing programs. The …